Last updated on June 2019

Efficacy and Safety of 2 Secukinumab Regimens in 90 kg or Higher Subjects With Moderate to Severe Chronic Plaque-type Psoriasis


Brief description of study

Demonstrate superiority of secukinumab high dose over standard dose in heavy body weight subjects with moderate to severe plaque psoriasis.

Detailed Study Description

A 52-week multicenter, randomized, double-blind, parallel-group trial in approximately 330 subjects with moderate to severe chronic plaque-type psoriasis of body weight 90 kg or higher at time of randomization.

The study consists of 4 periods: screening (up to 4 weeks), treatment Period 1 (16 weeks), treatment Period 2 (36 weeks), and post-treatment follow-up (8 weeks).

Subjects will be randomized using a 1:1 ratio to the following groups: Secukinumab 300 mg every 2 weeks; Secukinumab 300 mg every 4 weeks.

In addition, subjects from the 300 mg every 4 weeks group who do not achieve PASI 90 response at Week 16 will be randomized using a 1:1 ratio to either remain on secukinumab 300 mg every 4 weeks or receive secukinumab 300 mg every 2 weeks starting at Week 16, until the end of treatment.

Clinical Study Identifier: NCT03504852

Find a site near you

Start Over

Novartis Investigative Site

Birmingham, AL United States
  Connect »

Novartis Investigative Site

Phoenix, AZ United States
  Connect »

Novartis Investigative Site

Sacramento, CA United States
  Connect »

Novartis Investigative Site

San Diego, CA United States
  Connect »

Novartis Investigative Site

Santa Monica, CA United States
  Connect »

Novartis Investigative Site

Centennial, CO United States
  Connect »

Novartis Investigative Site

Ormond Beach, FL United States
  Connect »

Novartis Investigative Site

West Palm Beach, FL United States
  Connect »

Novartis Investigative Site

Alpharetta, GA United States
  Connect »

Novartis Investigative Site

Snellville, GA United States
  Connect »

Novartis Investigative Site

Indianapolis, IN United States
  Connect »

Novartis Investigative Site

New Albany, IN United States
  Connect »

Novartis Investigative Site

Louisville, KY United States
  Connect »

Novartis Investigative Site

Owensboro, KY United States
  Connect »

Novartis Investigative Site

Fridley, MN United States
  Connect »

Novartis Investigative Site

Saint Joseph, MO United States
  Connect »

Novartis Investigative Site

East Windsor, NJ United States
  Connect »

Novartis Investigative Site

Forest Hills, NY United States
  Connect »

Novartis Investigative Site

New York, NY United States
  Connect »

Novartis Investigative Site

Charlotte, NC United States
  Connect »

Novartis Investigative Site

Winston-Salem, NC United States
  Connect »

Novartis Investigative Site

Fairborn, OH United States
  Connect »

Novartis Investigative Site

Oregon City, OR United States
  Connect »

Novartis Investigative Site

Portland, OR United States
  Connect »

Novartis Investigative Site

Charleston, SC United States
  Connect »

Novartis Investigative Site

Houston, TX United States
  Connect »

Novartis Investigative Site

Mesquite, TX United States
  Connect »

Novartis Investigative Site

Pflugerville, TX United States
  Connect »

Novartis Investigative Site

San Antonio, TX United States
  Connect »

Novartis Investigative Site

Norfolk, VA United States
  Connect »

Novartis Investigative Site

Wenatchee, WA United States
  Connect »

Novartis Investigative Site

Madison, WI United States
  Connect »

Novartis Investigative Site

Chelyabinsk, Russian Federation
  Connect »

Novartis Investigative Site

Ekaterinburg, Russian Federation
  Connect »

Novartis Investigative Site

Kazan, Russian Federation
  Connect »

Novartis Investigative Site

Krasnodar, Russian Federation
  Connect »

Novartis Investigative Site

Lipetsk, Russian Federation
  Connect »

Novartis Investigative Site

Saint Petersburg, Russian Federation
  Connect »

Novartis Investigative Site

Saratov, Russian Federation
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.